Moyamoya Disease

Overview

Moyamoya disease is a progressive disorder in which the internal carotid arteries and their major brain branches gradually narrow, reducing blood flow to the brain. In response, fragile small collateral vessels develop; on angiography these resemble a “puff of smoke,” which gives the disease its Japanese name. It can cause transient ischemic attacks, ischemic or hemorrhagic stroke, seizures, headaches, and cognitive decline. It commonly begins in childhood or between the thirties and forties, is more common in females and in East Asian populations, and may also occur as moyamoya syndrome alongside conditions such as sickle-cell disease, neurofibromatosis type 1, or Graves’ disease. MedlinePlus Genetics overview (medlineplus.gov)

Without treatment, symptoms and neurologic injury can worsen over time. The established disease-modifying clinical intervention is surgical revascularization—creating or encouraging new blood supply to the brain through direct bypass, indirect bypass, or both—rather than a drug that reverses the underlying vessel disease. Current European guidance supports revascularization for appropriately selected adults and children with ischemic disease and impaired brain blood flow, while acknowledging that much of the evidence base remains limited. ESO clinical guideline (pubmed.ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

From 2020 through August 8, 2026, the field has become more mechanistic and translational, with research concentrating on the susceptibility gene RNF213, abnormal endothelial and vascular smooth-muscle-cell behavior, inflammation, angiogenesis, and better ways to model the disease in human cells. The community is not close to a general curative therapy: no treatment has yet been shown to repair the underlying arterial disorder in people with typical moyamoya disease. However, molecular targets, patient-derived vascular organoids, metabolic interventions for a genetic moyamoya-like subtype, and noninvasive stroke-protection approaches are moving the field beyond surgery alone. RNF213 vascular-inflammation study Human vascular-organoid model (pubmed.ncbi.nlm.nih.gov)

Major Breakthroughs and Emerging Therapies

A central advance has been clarifying how RNF213, the strongest known susceptibility gene, may disrupt vascular biology. Structural work established that RNF213 is an unusually large enzyme with ATPase and ubiquitin-ligase functions, giving researchers a defined protein system to investigate rather than only a genetic association. RNF213 molecular structure (pubmed.ncbi.nlm.nih.gov) Subsequent cell studies found that reducing RNF213 function can impair angiogenesis, alter vascular smooth-muscle-cell contractile programs, disrupt communication between endothelial and smooth-muscle cells, and heighten inflammatory responses. RNF213 loss-of-function study (pubmed.ncbi.nlm.nih.gov) A 2023 study of patient vessels and experimental models further implicated RNF213 loss in abnormal angiogenesis through the Hippo signaling pathway, identifying a possible route for future drug targeting. Hippo-pathway study (pubmed.ncbi.nlm.nih.gov)

Gene editing is currently serving as a research tool rather than a treatment. Investigators used CRISPR-Cas9 to create RNF213-deficient human cerebral endothelial cells and found impaired endothelial-barrier function, a result that helps explain how vascular leakage and inflammatory-cell entry could contribute to disease progression. Endothelial-barrier study (pubmed.ncbi.nlm.nih.gov) There is not yet a clinical gene-editing or gene-replacement program for moyamoya disease; key unanswered questions include which RNF213 variants are truly causal, which cell types must be corrected, and how a therapy could be delivered safely to affected brain arteries.

A notable small-molecule lead is nicotinamide riboside (NR), a precursor used by cells to make NAD+, an essential metabolic cofactor. In a mouse model carrying a pathogenic ACTA2 variant that causes smooth-muscle dysfunction syndrome with moyamoya-like cerebrovascular disease, NR promoted smooth-muscle-cell maturation and reduced arterial occlusion, abnormal remodeling, and stroke after vascular injury. NR preclinical study (pubmed.ncbi.nlm.nih.gov) This is promising precision-medicine evidence, but it applies to an ACTA2-associated moyamoya-like condition rather than demonstrating efficacy in the broader and genetically diverse moyamoya population.

Remote ischemic conditioning (RIC) is another emerging, non-drug approach. It uses repeated brief, controlled reductions of blood flow to a limb—typically through a blood-pressure cuff—to trigger protective systemic responses. In a randomized pediatric pilot study, daily RIC was associated with fewer major adverse cerebrovascular events than sham treatment over follow-up, without severe RIC-related adverse events; it should nevertheless be considered an adjunctive experimental strategy, not a cure or substitute for indicated revascularization. Pediatric RIC randomized trial (pmc.ncbi.nlm.nih.gov)

Clinical Trials and Experimental Approaches

The most explicitly disease-targeted pharmacologic trial located is NCT06280482, a recruiting, open-label Phase 1 study sponsored by the University of Texas Health Science Center at Houston. It is testing 60 days of oral NR in an estimated 15 people with ACTA2-arginine-179 smooth-muscle dysfunction syndrome, including measures of safety, blood NAD+ levels, cerebral oxygenation/perfusion, cognition, and vascular outcomes. The registry listed no posted results and estimated primary completion for July 25, 2027; importantly, this is a trial for moyamoya-like disease in a defined genetic syndrome, not for typical RNF213-associated moyamoya disease. NCT06280482 trial record (clinicaltrials.gov)

RIC has generated the most substantial recent human interventional evidence in classic moyamoya disease. In a single-center randomized adult perioperative study of 44 people undergoing revascularization, the RIC group had fewer major neurologic complications than the sham group (18.2% versus 54.5%) and no reported RIC-related adverse events; the study was a pilot rather than a formal pivotal drug-development trial. Adult perioperative RIC pilot (pubmed.ncbi.nlm.nih.gov) The pediatric trial similarly supports feasibility and possible stroke-risk reduction, but both studies require larger multicenter replication before RIC could change standard care. Pediatric RIC randomized trial (pmc.ncbi.nlm.nih.gov)

Methodologies and Scientific Approaches

Researchers are combining patient vascular specimens, genomic sequencing, engineered endothelial and smooth-muscle-cell cultures, and transcriptomic profiling to identify the biological events that cause arterial narrowing and abnormal collateral formation. RNF213 knockdown studies have used RNA and splice-pattern analysis to map altered angiogenesis, inflammatory signaling, cytoskeletal organization, and endothelial–smooth-muscle communication. RNF213 loss-of-function study (pubmed.ncbi.nlm.nih.gov)

The most important platform development is the use of induced pluripotent stem cells (iPSCs), which are adult cells reprogrammed into stem-cell-like cells and then differentiated into three-dimensional vascular organoids. In 2026, RNF213-deficient iPSC-derived vascular organoids reproduced disrupted endothelial networks, abnormal basement membranes, and dysregulated angiogenesis-related gene programs, creating a potential system for drug screening. RNF213 vascular-organoid model (pubmed.ncbi.nlm.nih.gov) Separate patient-derived organoid and single-cell work identified abnormal smooth-muscle-cell accumulation and implicated TUBA4A/TUBB4B-associated signaling in pathologic vascular remodeling. Organoid and single-cell profiling study (pubmed.ncbi.nlm.nih.gov)

Leading Institutions and Funding

Tohoku University in Japan remains a major RNF213 and vascular-biology center, with investigators using vascular-cell models and transcriptomics to study gene–inflammation interactions. Tohoku RNF213 study (pubmed.ncbi.nlm.nih.gov) Japan’s KAKENHI program awarded Tohoku University’s endothelial–smooth-muscle interaction and RNF213 project ¥15.6 million for fiscal year 2024, illustrating continued public investment in mechanism-focused research. KAKENHI project 23H00433 (kaken.nii.ac.jp)

Other leading contributors include the University of Texas Health Science Center at Houston, which sponsors the NR Phase 1 trial in ACTA2-related smooth-muscle dysfunction syndrome, and Chinese clinical-research groups centered at Beijing Tiantan Hospital, Capital Medical University, and the China National Clinical Research Center for Neurological Diseases, which are developing iPSC-organoid models and vascular-remodeling targets. NR Phase 1 trial RNF213 vascular-organoid model Organoid and single-cell profiling study (clinicaltrials.gov)

Strengths, Limitations, and Challenges

The strongest recent progress is the convergence of genetics, patient tissue, advanced cell models, and early human trials. RNF213-centered studies increasingly connect inherited susceptibility to measurable endothelial dysfunction, inflammation, and smooth-muscle-cell remodeling, while iPSC-derived organoids enable researchers to test candidate treatments in human vascular systems rather than relying solely on animal or generic cell models. Endothelial-barrier study RNF213 vascular-organoid model (pubmed.ncbi.nlm.nih.gov)

The major limitation is that moyamoya disease is biologically heterogeneous: RNF213 variants confer susceptibility but do not explain every case, and ACTA2-associated moyamoya-like disease may not respond to the same therapy as typical disease. Experimental results also often come from small cohorts, cultured cells, or models that do not fully reproduce the terminal internal-carotid-artery pathology in humans. RNF213 loss-of-function study (pmc.ncbi.nlm.nih.gov) Clinical evidence remains limited in size and quality, and current guidelines emphasize that more rigorous studies are needed to define optimal treatment choices and timing. ESO clinical guideline (pubmed.ncbi.nlm.nih.gov)

Outlook and Future Directions

A cure for moyamoya disease is not imminent, but the field is approaching the prerequisites for rational disease-modifying therapy: reproducible human vascular models, molecular biomarkers, genetically stratified patient groups, and early proof-of-concept interventions. The milestones to watch are validation of RNF213 and smooth-muscle-cell targets across diverse patient populations; drug-screening results from patient-derived vascular organoids; completion of the NR Phase 1 study in ACTA2-related disease; and larger, multicenter RIC trials that test whether the encouraging pilot findings translate into durable reductions in stroke and surgical complications. NCT06280482 trial record Adult perioperative RIC pilot Organoid and single-cell profiling study (clinicaltrials.gov)

References

• Moyamoya disease: MedlinePlus Genetics overview — U.S. National Library of Medicine, 2017.
• European Stroke Organisation guideline on moyamoya angiopathy — Bersano et al., 2023.
• RNF213 molecular structure and ubiquitin-transfer mechanism — Ahel et al., 2020.
• RNF213 loss of function reshapes vascular transcriptome and inflammation — Zhang et al., 2022.
• RNF213 loss of function and Hippo-pathway angiogenesis — Ye et al., 2023.
• RNF213 regulates endothelial barrier function — Roy et al., 2022.
• Nicotinamide riboside mitigates ACTA2-associated moyamoya-like disease in mice — Huang et al., 2023.
• Nicotinamide riboside Phase 1 trial in smooth-muscle dysfunction syndrome — ClinicalTrials.gov, 2025.
• Remote ischemic conditioning in pediatric moyamoya disease — Zhang et al., 2024.
• Remote ischemic conditioning during adult moyamoya revascularization — Yang et al., 2023.
• RNF213-deficient iPSC vascular organoids model moyamoya vasculopathy — Wu et al., 2026.
• Organoid modeling and single-cell profiling of smooth-muscle migration — He et al., 2026.
• KAKENHI project: endothelial–smooth-muscle interaction and RNF213 — Japan Society for the Promotion of Science, 2024.